Moderna CEO discusses future plans following melanoma vaccine trial success
Moderna's chief executive Stéphane Bancel highlighted the upcoming presentation of Phase 3 results for the mRNA melanoma therapy intismeran and outlined its implications for the company's research direction.
Moderna chief executive Stéphane Bancel said the company will present Phase 3 data for its customized mRNA melanoma therapy, intismeran, at the European Society for Medical Oncology meeting in Madrid. The trial, developed in partnership with Merck, aims to demonstrate improved outcomes for patients with melanoma.
Bancel noted that the project has been a decade in the making and that many in the field were skeptical about the feasibility of cancer vaccines. He said the upcoming results reflect the collaborative effort of numerous researchers and could influence Moderna's broader research and business strategies.
"We’ve been working on intismeran for 10 years. Most people in the field thought this was never going to work, and many people had tried cancer vaccines before. But we were convinced, so it has been really special to be able to see all this work by so many people coming together to help patients."